Proteome Exploration of Human Coronaviruses for Identifying Novel Vaccine Candidate: A Hierarchical Subtractive Genomics and Reverse Vaccinology Approach.

Q3 Biochemistry, Genetics and Molecular Biology
Hesam Dorosti, Mahboubeh Zarei, Navid Nezafat
{"title":"Proteome Exploration of Human Coronaviruses for Identifying Novel Vaccine Candidate: A Hierarchical Subtractive Genomics and Reverse Vaccinology Approach.","authors":"Hesam Dorosti,&nbsp;Mahboubeh Zarei,&nbsp;Navid Nezafat","doi":"10.2174/1872208316666220504234800","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The SARS-CoV-2 has been responsible for infecting more than 613,615,658 people in 222 countries by September 11, 2022, of which 6,516,076 have died. COVID-19 was introduced by World Health Organization as a global concern and a pandemic disease due to its prevalence.</p><p><strong>Objective: </strong>Developing preventive or therapeutic medications against 2019-nCoV is an urgent need, and has been deemed as a high priority among scientific societies; in this regard, the production of effective vaccines is one of the most significant and high-priority requirements. Because of costly and time-consuming process of vaccine design, different immunoinformatics methods have been developed.</p><p><strong>Methods: </strong>At the beginning of vaccine design, the proteome study is essential. In this investigation, the whole human coronavirus proteome was evaluated using the proteome subtraction strategy. Out of 5945 human coronavirus proteins, five new antigenic proteins were selected by analyzing the hierarchical proteome subtraction, and then their various physicochemical and immunological properties were investigated bioinformatically.</p><p><strong>Results: </strong>All five protein sequences are antigenic and non-allergenic proteins; moreover, the spike protein group, including spike glycoprotein (E2) (Peplomer protein), spike fragment and spike glycoprotein fragment, showed acceptable stability, which can be used to design new vaccines against human coronaviruses.</p><p><strong>Conclusion: </strong>The selected peptides and the other proteins introduced in this study (HE, orf7a, SARS_X4 domain-containing protein and protein 8) can be employed as a suitable candidate for developing a novel prophylactic or therapeutic vaccine against human coronaviruses.</p>","PeriodicalId":21064,"journal":{"name":"Recent patents on biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recent patents on biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1872208316666220504234800","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 1

Abstract

Background: The SARS-CoV-2 has been responsible for infecting more than 613,615,658 people in 222 countries by September 11, 2022, of which 6,516,076 have died. COVID-19 was introduced by World Health Organization as a global concern and a pandemic disease due to its prevalence.

Objective: Developing preventive or therapeutic medications against 2019-nCoV is an urgent need, and has been deemed as a high priority among scientific societies; in this regard, the production of effective vaccines is one of the most significant and high-priority requirements. Because of costly and time-consuming process of vaccine design, different immunoinformatics methods have been developed.

Methods: At the beginning of vaccine design, the proteome study is essential. In this investigation, the whole human coronavirus proteome was evaluated using the proteome subtraction strategy. Out of 5945 human coronavirus proteins, five new antigenic proteins were selected by analyzing the hierarchical proteome subtraction, and then their various physicochemical and immunological properties were investigated bioinformatically.

Results: All five protein sequences are antigenic and non-allergenic proteins; moreover, the spike protein group, including spike glycoprotein (E2) (Peplomer protein), spike fragment and spike glycoprotein fragment, showed acceptable stability, which can be used to design new vaccines against human coronaviruses.

Conclusion: The selected peptides and the other proteins introduced in this study (HE, orf7a, SARS_X4 domain-containing protein and protein 8) can be employed as a suitable candidate for developing a novel prophylactic or therapeutic vaccine against human coronaviruses.

人类冠状病毒蛋白质组学研究用于鉴定新型候选疫苗:层次减法基因组学和反向疫苗学方法。
背景:截至2022年9月11日,SARS-CoV-2已在222个国家感染超过613,615,658人,其中6,516,076人死亡。COVID-19因其普遍性被世界卫生组织列为全球关注的疾病和大流行疾病。目的:开发针对新型冠状病毒的预防或治疗药物是迫切需要,已被科学界视为高度优先事项;在这方面,生产有效疫苗是最重要和最优先的要求之一。由于疫苗设计成本高、耗时长,人们开发了不同的免疫信息学方法。方法:在疫苗设计之初,蛋白质组学研究是必不可少的。本研究采用蛋白质组减法对整个人冠状病毒蛋白质组进行评估。从5945种人冠状病毒蛋白中,通过分层蛋白质组减法分析筛选出5种新的抗原蛋白,并对其理化和免疫学特性进行生物信息学研究。结果:5个蛋白序列均为抗原性、非致敏性蛋白;此外,包括刺突糖蛋白(E2) (Peplomer蛋白)、刺突片段和刺突糖蛋白片段在内的刺突蛋白组表现出可接受的稳定性,可用于设计新的抗人冠状病毒疫苗。结论:所筛选的多肽和本研究引入的其他蛋白(HE、orf7a、SARS_X4结构域蛋白和蛋白8)可作为开发新型冠状病毒预防或治疗性疫苗的合适候选蛋白。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Recent patents on biotechnology
Recent patents on biotechnology Biochemistry, Genetics and Molecular Biology-Biotechnology
CiteScore
2.90
自引率
0.00%
发文量
51
期刊介绍: Recent Patents on Biotechnology publishes review articles by experts on recent patents on biotechnology. A selection of important and recent patents on biotechnology is also included in the journal. The journal is essential reading for all researchers involved in all fields of biotechnology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信